Semaglutide's MASH approval: what the new liver disease licence actually means

What is MASH, and why does this approval matter?

MASH stands for metabolic dysfunction-associated steatohepatitis. It is a progressive form of fatty liver disease in which fat accumulation triggers inflammation and, over time, scarring of liver tissue, a process called fibrosis. Left untreated, advanced fibrosis can lead to cirrhosis and liver failure. MASH is closely linked to obesity, type 2 diabetes and metabolic syndrome, which is why a medicine already used in weight management attracted serious research interest as a potential liver treatment.

Until 3 July 2026, there were very few licensed pharmaceutical options for MASH in the UK. The MHRA's conditional approval of semaglutide for adults with moderate-to-advanced fibrosis therefore represents a meaningful step forward. "Conditional" approval means the licence is granted on the basis of promising trial data, with the manufacturer committed to providing further evidence to confirm long-term benefit. It is the same regulatory pathway the MHRA uses when the potential benefit of a medicine in a serious condition outweighs the current uncertainty about the full evidence picture.

For patients already living with MASH alongside obesity or type 2 diabetes, the clinical picture is often complex. This approval opens a conversation with their specialist about whether semaglutide could address more than one aspect of their condition at once, though that conversation is for the prescriber, not a pharmacy website, to lead.

How does the MASH licence differ from Wegovy's weight-loss authorisation?

Wegovy's weight-management licence covers adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. The history of Wegovy's weight-loss approval in the UK goes back to 2023, when NICE recommended it under specific specialist-service criteria.

The MASH indication is different in scope. It targets adults who have been diagnosed with MASH and have evidence of moderate-to-advanced liver fibrosis, that is a clinical diagnosis, typically confirmed through liver biopsy or validated non-invasive testing, rather than a BMI calculation. Someone could theoretically meet the MASH criteria without meeting the BMI threshold for the weight-management indication, and vice versa.

The practical upshot is that a person asking their hepatologist or GP whether semaglutide is right for their MASH will go through a separate assessment pathway from someone approaching a weight-management service. At our Wegovy treatment page you can read about how the weight-management licence works in a private prescribing context; the MASH indication, because it requires specialist liver-disease diagnosis and monitoring, sits firmly within NHS hepatology services rather than a private weight-management consultation.

Cost context is worth noting briefly: if you are exploring Wegovy for weight management rather than MASH, understanding what Wegovy costs privately in the UK helps set expectations before you start a consultation.

What did the clinical evidence show?

The MHRA's conditional approval was based on trial data demonstrating that semaglutide produced meaningful improvements in liver histology (measurable reductions in liver inflammation and fibrosis grade) compared with placebo, in adults with confirmed MASH. "Conditional" approval does not mean the evidence was weak; it means the MHRA judged that the benefit to patients with a serious, underserved condition was clear enough to act now, while the manufacturer gathers longer-term outcome data.

Semaglutide's mechanism is relevant here. As a GLP-1 receptor agonist, it reduces appetite and slows the rate at which the stomach empties. In MASH, researchers believe the reduction in body weight and the direct effects of GLP-1 receptor activation on liver metabolism both contribute to improvement in fibrosis. The weight-loss component matters because excess liver fat is itself a driver of inflammation, but the data suggest the benefit may not be purely explained by weight change alone.

For context on semaglutide's broader clinical profile, the NHS medicines page for semaglutide covers the licensed uses, common side effects and how the medicine works in plain language. The MASH indication will be reflected in updated prescribing information over time.

What does this mean for people currently using or considering Wegovy?

If you are already using Wegovy for weight management and you also have a diagnosis of MASH, tell your prescriber. They can review whether your current treatment remains appropriate and whether specialist liver-disease input would be helpful.

If you are considering Wegovy for weight management but do not have a MASH diagnosis, the new approval does not change the eligibility criteria that apply to you. Our semaglutide information page covers what the weight-management licence requires and what to expect from treatment. A prescriber still needs to assess your full medical history before treatment is issued. Wegovy is not recommended during pregnancy, whilst breastfeeding or when trying to conceive, and it is not licensed for anyone under 18.

Practically speaking, Wegovy for weight management is dispensed as a once-weekly injection. When your treatment arrives, it comes in plain, unbranded packaging via tracked DPD delivery, with all the information you need inside. The MASH approval does not change the pen format, storage requirements or injection schedule for people using the medicine for weight management.

The regulatory picture for semaglutide continues to move quickly, and if you want to understand how the MASH authorisation fits into the broader story of how Wegovy gained approval in the UK, that background is worth reading alongside the timeline below. A fuller timeline of semaglutide's UK approvals puts each development in order, from the original diabetes licence through to the most recent MASH authorisation. If you have questions about whether weight-management treatment with semaglutide is right for your situation, check your eligibility with our prescribers, the consultation is free, and a clinician reviews every application the same day.